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Abstract
From 1 January to 31 December 2014, 27 institu-
tions around Australia participated in the Australian 
Staphylococcal Sepsis Outcome Programme 
(ASSOP). The aim of ASSOP 2014 was to deter-
mine the proportion of Staphylococcus aureus 
bacteraemia (SAB) isolates in Australia that are 
antimicrobial resistant, with particular emphasis on 
susceptibility to methicillin and to characterise the 
molecular epidemiology of the isolates. Overall, 
18.8% of the 2,206 SAB episodes were methicillin 
resistant, which was significantly higher than that 
reported in most European countries. The 30-day 
all-cause mortality associated with methicillin-
resistant SAB was 23.4%, which was significantly 
higher than the 14.4% mortality associated with 
methicillin-sensitive SAB (P<0.0001). With the 
exception of the ß-lactams and erythromycin, 
antimicrobial resistance in methicillin-sensitive 
S. aureus remains rare. However in addition to the 
ß-lactams, approximately 50% of methicillin-resist-
ant S. aureus (MRSA) were resistant to erythromy-
cin and ciprofloxacin and approximately 15% were 
resistant to co-trimoxazole, tetracycline and gen-
tamicin. When applying the European Committee 
on Antimicrobial Susceptibility Testing breakpoints, 
teicoplanin resistance was detected in 2 S. aureus 
isolates. Resistance was not detected for vancomy-
cin or linezolid. Resistance to non-beta-lactam anti-
microbials was largely attributable to 2 healthcare-
associated MRSA clones; ST22-IV [2B] (EMRSA-15) 
and ST239-III [3A] (Aus-2/3 EMRSA). ST22-IV [2B] 
(EMRSA-15) has become the predominant health-
care associated clone in Australia. Sixty per cent of 
methicillin-resistant SAB were due to community-
associated (CA) clones. Although polyclonal, 
almost 44% of community-associated clones 
were characterised as ST93-IV [2B] (Queensland 
CA-MRSA) and ST1-IV [2B] (WA1). CA-MRSA, in 
particular the ST45-V [5C2&5] (WA84) clone, has 
acquired multiple antimicrobial resistance determi-
nants including ciprofloxacin, erythromycin, clinda-
mycin, gentamicin and tetracycline. As CA-MRSA 
is well established in the Australian community it 
is important that antimicrobial resistance patterns 
in community and healthcare-associated SAB is 
monitored as this information will guide therapeu-
tic practices in treating S. aureus sepsis. Commun 
Dis Intell 2016;40(2):E244–E254.
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Introduction
Globally, Staphylococcus aureus is one of the most 
frequent causes of hospital-acquired and commu-
nity-acquired blood stream infections.1 Although 
there are a wide variety of manifestations of seri-
ous invasive infection caused by S. aureus, in the 
great majority of these cases the organism can 
be detected in blood cultures. Therefore, SAB is 
considered a very useful marker for serious invasive 
infection.2
Although prolonged antimicrobial therapy and 
prompt source control are used to treat SAB,3 
mortality ranges from as low as 2.5% to as high as 
40%.4– 6 Mortality rates however, are known to vary 
significantly with patient age, clinical manifesta-
tion, co-morbidities and methicillin resistance.7,8 
A prospective study of SAB conducted in 27 labo-
ratories in Australia and New Zealand found a 
30-day all-cause mortality of 20.6%.9 On univari-
ate analysis, increased mortality was significantly 
associated with older age, European ethnicity, 
methicillin resistance, infections not originating 
from a medical device, sepsis syndrome, pneumo-
nia/empyema and treatment with a glycopeptide or 
other non-ß-lactam antibiotic.
The Australian Group on Antimicrobial Resistance 
(AGAR), a network of laboratories located across 
Australia, commenced surveillance of antimicro-
bial resistance in S. aureus in 1986.10 In 2013 AGAR 
commenced the Australian Staphylococcal Sepsis 
Outcome Programme (ASSOP).11 The primary 
objective of ASSOP 2014 was to determine the 
proportion of SAB isolates demonstrating antimi-
crobial resistance with particular emphasis on:
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1. assessing susceptibility to methicillin
2. molecular epidemiology of methicillin 
resistant S. aureus (MRSA).
Methods
Twenty-seven laboratories from all 8 Australian 
states and territories participated in the program 
in 2014.
From 1 January to 31 December 2014, the 27 labo-
ratories collected all S. aureus isolated from blood 
cultures. S. aureus with the same antimicrobial 
susceptibility profiles isolated from a patient’s 
blood culture within 14 days of the first positive 
culture were excluded. A new S. aureus sepsis 
episode in the same patient was recorded if it was 
identified by a culture of blood collected more 
than 14 days after the last positive culture. Data 
were collected on age, sex, date of admission and 
discharge (if admitted), and mortality at 30 days 
from date of first positive blood culture. To avoid 
interpretive bias, no attempt was made to assign 
attributable mortality. Each episode of bacterae-
mia was designated healthcare onset if the first 
positive blood culture(s) in an episode were col-
lected > 48 hours after admission.
Laboratory testing
Participating laboratories performed antimicrobial 
susceptibility testing using the Vitek2® (bio-
Mérieux, France) or the Phoenix™ (BD, USA) 
automated microbiology systems according to the 
manufacturer’s instructions. S. aureus was identi-
fied by morphology and positive results of at least 
one of the following tests: Vitek MS® (bioMérieux, 
France), matrix-assisted laser desorption ioniza-
tion biotyper (Bruker Daltonics, Germany), slide 
coagulase, tube coagulase, appropriate growth on 
chromogenic agar and demonstration of deoxyri-
bonuclease production. Additional tests such as 
fermentation of mannitol, growth on mannitol-salt 
agar or polymerase chain reaction (PCR) for the 
presence of the nuc gene may have been performed 
for confirmation.
Minimum inhibitory concentration (MIC) data 
and isolates were referred to the Australian 
Collaborating Centre for Enterococcus and 
Staphylococcus Species (ACCESS) Typing and 
Research. Clinical and Laboratory Standards 
Institute (CLSI)12 and European Committee 
on Antimicrobial Susceptibility Testing 
(EUCAST)13 breakpoints were utilised for inter-
pretation. Isolates with a resistant or an interme-
diate category were classified as non-susceptible. 
Linezolid and daptomycin non-susceptible iso-
lates were retested by Etest® (bioMérieux) using 
the Mueller-Hinton agar recommended by the 
manufacturer. S. aureus ATCC 29213 was used 
as the control strain. High level mupirocin resist-
ance was determined using a mupirocin 200 μg 
disk according to CLSI guidelines on all isolates 
with a mupirocin MIC > 8 mg/L by Vitek2® or 
> 256 mg/L by Phoenix™.12 Multi-resistance was 
defined as resistance to 3 or more of the follow-
ing non-ß-lactam antimicrobials: vancomycin, 
teicoplanin, erythromycin/clindamycin, tetracy-
cline, ciprofloxacin, gentamicin, co-trimoxazole, 
fusidic acid, rifampicin, high level mupirocin, or 
linezolid.
Electrophoresis of chromosomal DNA was per-
formed as previously described on all MRSA using 
contour-clamped homogeneous electric field DR 
III system (Bio-Rad Laboratories Pty Ltd, USA).14 
Chromosomal patterns were examined visually, 
scanned with a Quantity One software (Bio-Rad 
Laboratories Pty Ltd, USA), and digitally analysed 
using FPQuest (Applied Maths NV, Belgium). 
Multilocus sequence typing (MLST) was per-
formed on all unique pulsed-field types as previ-
ously described.15 The sequences were submitted to 
the Multi Locus Sequence Typing on-line database 
(http://www.mlst.net) where an allelic profile was 
generated and an ST assigned.
SCCmec typing was performed on all MRSA with 
a unique pulsed-field pattern using the Clondiag 
S. aureus Genotyping Array Hybridisation Kit 
(Alere, USA) as previously described.16
Detection of Panton-Valentine leucocidin (PVL) 
determinants and mecA was performed by PCR on 
all MRSA as previously described.17,18
Chi-square tests for comparison of 2 propor-
tions and calculation of 95% confidence intervals 
(95%CI) were performed using MedCalc for 
Windows, version 12.7 (Medcalc Software, Ostend 
Belgium).
Approval to conduct the prospective data collection 
was given by the research ethics committee associ-
ated with each participating laboratory.
Results
From 1 January to 31 December 2014, 2,206 unique 
episodes of S. aureus bacteraemia were identi-
fied. A significant difference (P < 0.0001) was 
seen in patient sex with 63.2% (1,395) being male 
(95% CI 60.6–65.7). The average age of patients 
was 59 years ranging from 0 to 101 years with a 
median age of 62 years. Overall, 73.2% (1,615) of 
the 2,206 episodes were community onset (95% CI 
71.0%–75.3%). All-cause mortality at 30-days was 
16.1% (95% CI 14.5–17.8). Methicillin-resistant 
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SAB mortality was 23.4% (95% CI 19.1 to 28.1), 
which was significantly higher than methicillin-
susceptible SAB mortality (14.4%, 95% CI 12.7 to 
16.3, P < 0.0001).
Methicillin-sensitive Staphylococcus aureus 
antimicrobial susceptibility
Overall, 81.2% (1,792) of the 2,206 isolates were 
methicillin sensitive of which 77.0% (1,380) 
were penicillin resistant (MIC > 0.12 mg/L). 
However as ß-lactamase was detected in 87 phe-
notypically penicillin susceptible isolates, 81.9% 
of Methicillin-sensitive Staphylococcus aureus 
(MSSA) were considered penicillin resistant. Apart 
from erythromycin non-susceptibility, resistance 
to the non-ß-lactam antimicrobials among MSSA 
was rare, ranging from < 0.1% to 4.1% (Table 1). 
Four isolates were reported as non-susceptible to 
daptomycin by Vitek2®. By Etest® all isolates had 
MICs ≤ 1 mg/L and were therefore considered 
susceptible. Two isolates were reported as linezolid 
resistant (MIC > 8 mg/L) by Vitek2®. However by 
Etest® both isolates had a MIC ≤ 4 mg/L (1.0 and 
2.0 mg/L) and were therefore considered linezolid 
susceptible. When using the EUCAST resistant 
breakpoint of > 2 mg/L 1 isolate was teicoplanin 
resistant (MIC = 4 mg/L). However using the 
CLSI resistant breakpoint of > 8 mg/L the isolate 
was classified susceptible. All MSSA were vanco-
mycin susceptible. Twenty-eight (1.6%) of the 1,792 
isolates had high level mupirocin resistance, of 
which 19 isolates were referred from Queensland. 
Inducible resistance to clindamycin was deter-
mined by the Vitek2® susceptibility system. Of 
the 1,622 isolates tested, 9.1% (147) were erythro-
mycin non-susceptible/clindamycin intermediate/
susceptible (CLSI and EUCAST breakpoints) of 
which 75.5% (111) were classified as having induc-
ible clindamycin resistance. Multi-resistance was 
uncommon in MSSA (1.7%, 30/1,792).
There were no significant differences in interpre-
tation for any drug when CLSI or EUCAST non-
susceptibility breakpoints were utilised (P > 0.05).
Table 1: The number and proportion of methicillin sensitive Staphylococcus aureus isolates 
non-susceptible to penicillin and the non-β-lactam antimicrobials, Australia, 2014
Antimicrobial Tested Breakpoint (mg/L)
Non-susceptible
n %
Penicillin 1,792 >0.12* 1,467 81.8
Vancomycin 1,792 >2* 0 0.0
Teicoplanin 1,792 >8† 0 0.0
>2‡ 1 0.1
Rifampicin 1,741 >1† 4 0.2
Fusidic acid 1,791 >1‡ 74 4.1
Gentamicin 1,792 >4† 14 0.8
>1‡ 18 1.0
Erythromycin 1,790 >2† 177 9.9
>1‡ 181 10.1
Clindamycin 1,790 >0.5† 30 1.7
>0.25 31 1.7
Tetracycline 1,790 >4† 55 3.1
>1‡ 61 3.4
Co-trimoxazole 1,791 >2/38* 40 2.2
Ciprofloxacin 1,782 >1* 54 3.0
Nitrofurantoin 1,702 >32† 20 1.2
Daptomycin 1,791 >1* 0 0.0
Linezolid 1,792 >4* 0 0.0
* Clinical and Laboratory Standards Institute (CLSI) and European Committee on Antimicrobial Susceptibility Testing 
(EUCAST) non-susceptible breakpoint.
† CLSI non-susceptible breakpoint.
‡ EUCAST non-susceptible breakpoint.
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Methicillin-resistant Staphylococcus aureus 
antimicrobial susceptibility
The proportion of S. aureus that were MRSA was 
18.8% (95%CI 17.2–20.5). The 414 MRSA identi-
fied were either cefoxitin screen positive by Vitek2® 
(401) or had a cefoxitin MIC > 8 by Phoenix™ 
(13). All 414 MRSA isolates were phenotypically 
penicillin resistant. Among the MRSA isolates, 
non-susceptibility to non-ß-lactam antimicrobials 
was common except for rifampicin, fusidic acid 
and nitrofurantion where resistance was below 
4.1% (Table 2). There were 6 isolates reported 
by Vitek2® as non-susceptible to daptomycin. By 
Etest® 3 isolates had MICs ≤ 1 mg/L and were 
therefore considered susceptible. Three isolates 
had MICs > 1 mg/L (1.5, 3 and 4 mg/L) and 
were considered non-susceptible. By Vitek2®, 2 
isolates were linezolid resistant (MIC > 8 mg/L). 
However by Etest® both isolates had an MIC 
≤ 4 mg/L (1 and 1.5 mg/L) and were therefore 
considered linezolid susceptible. When using the 
EUCAST resistant breakpoint of > 2 mg/L, 1 
isolate was teicoplanin resistant (MIC = 4 mg/L). 
However, using the CLSI resistant breakpoint of 
> 8 mg/L the isolate was classified susceptible. All 
MRSA were vancomycin susceptible. Eight (1.9%) 
of the 414 MRSA isolates had high level mupirocin 
resistance of which five isolates were referred from 
Queensland. Inducible resistance to clindamycin 
was determined by the Vitek2® susceptibility 
system. Of the 352 isolates tested by Vitek2®, 
31.2% (110) were erythromycin non-susceptible/
clindamycin intermediate/susceptible (CLSI and 
EUCAST breakpoints) of which 88.2% (97) were 
classified as having inducible clindamycin resist-
ance. Multi-resistance was common in MRSA 
(24.4%, 101/414).
There were no significant differences in interpre-
tation for any drug when CLSI or EUCAST non- 
susceptibility breakpoints were utilised (P > 0.05).
Methicillin-resistant Staphylococcus aureus 
molecular epidemiology
Of the 414 MRSA identified, 403 were referred 
to ACCESS Typing and Research for strain char-
acterisation. Based on molecular typing, 40.4% 
(163) and 59.6% (240) of isolates were classified 
Table 2: The number and proportion of methicillin-resistant Staphylococcus aureus isolates 
non-susceptible to penicillin and the non-β-lactam antimicrobials, Australia, 2014
Antimicrobial Tested Breakpoint (mg/L)
Non-susceptible (%)
n %
Penicillin 414 >0.12* 414 100.0
Vancomycin 414 >2* 0 0.0
Teicoplanin 414 >8† 0 0.0
>2‡ 1 0.2
Rifampicin 412 >1† 4 1.0
Fusidic acid 414 >1‡ 17 4.1
Gentamicin 414 >4† 67 16.2
>1‡ 74 17.9
Erythromycin 414 >2† 204 49.3
>1‡ 204 49.3
Clindamycin 414 >0.5† 68 16.4
>0.25‡ 70 16.9
Tetracycline 414 >4† 65 15.7
>1‡ 81 19.6
Co-trimoxazole 413 >2/38* 61 14.8
Ciprofloxacin 414 >1* 212 51.2
Nitrofurantoin 407 >32† 13 3.2
Daptomycin 412 >1* 3 0.7
Linezolid 414 >4* 0 0.0
* Clinical and Laboratory Standards Institute (CLSI) and European Committee on Antimicrobial Susceptibility Testing 
(EUCAST) non-susceptible breakpoint.
† CLSI non-susceptible breakpoint.
‡ EUCAST non-susceptible breakpoint.
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as healthcare-associated MRSA (HA-MRSA) and 




For the 163 HA-MRSA strains, 46.6% (76) were 
epidemiologically classified as hospital onset and 
53.4% (87) were classified as community onset. 
Table 3: Proportion of healthcare-associated and community-associated methicillin-resistant 






n %* n % n %† n %
Healthcare-associated MRSA
ST22-IV [2B] (EMRSA-15) 119 29.5 52 43.7 67 56.3 1 0.8
ST239-III [3A] (Aus-2/3) 43 10.7 23 53.5 20 46.5 0 0.0
ST5-II [2A] (USA100) 1 0.2 1 100.0 0 0.0 0 0.0
Total 163 40.4 76 46.6 87 53.4 1 0.6
Community-associated MRSA
ST93-IV [2B] (Queensland) 60 14.9 13 21.7 47 78.3 56 93.3
ST1-IV [2B] (WA1) 45 11.2 11 24.4 34 75.6 4 8.9
ST45-V [5C2&5] (WA84) 30 7.4 12 40.0 18 60.0 0 0.0
ST30-IV [2B] (SWP) 20 5.0 4 20.0 16 80.0 18 90.0
ST5-IV [2B] (WA3) 20 5.0 6 30.0 14 70.0 0 0.0
ST78-IV [2B] (WA2) 11 2.7 5 45.5 6 54.5 1 9.1
ST188-IV [2B] (WA38) 5 1.2 2 40.0 3 60.0 0 0.0
ST1-V [5C2] 5 1.2 1 20.0 4 80.0 0 0.0
ST8-IV [2B] (USA300) 5 1.2 0 0.0 5 100.0 5 100.0
ST5-IV [2B] (WA71) 4 1.0 0 0.0 4 100.0 0 0.0
ST72-IV [2B] (Korean) 4 1.0 3 75.0 1 25.0 0 0.0
ST5-IV [2B] (WA121) 4 1.0 0 0.0 4 100.0 4 100.0
ST835-IV [2B] (WA48) 4 1.0 0 0.0 4 100.0 0 0.0
ST953-IV [2B] (WA54) 3 0.7 0 0.0 3 100.0 0 0.0
ST5-V [5C2] (WA81) 3 0.7 0 0.0 3 100.0 0 0.0
ST45-IV [2B] (WA75) 3 0.7 0 0.0 3 100.0 0 0.0
ST5-V [5C2] (WA123) 3 0.7 0 0.0 3 100.0 0 0.0
ST59-IV [2B] (WA15) 2 0.5 1 50.0 1 50.0 0 0.0
ST1420-IV [2B] (WA126) 2 0.5 0 0.0 2 100.0 1 50.0
ST6-IV [2B] (WA51) 1 0.2 1 100.0 0 0.0 0 0.0
ST5-IV [2B] 1 0.2 0 0.0 1 100.0 0 0.0
ST5-IV [2B] (WA105) 1 0.2 0 0.0 1 100.0 0 0.0
ST75-IV (2B] (WA8) 1 0.2 1 100.0 0 0.0 0 0.0
ST5-V [5C2] WA14 1 0.2 0 0.0 1 100.0 0 0.0
ST5-V [5C2] WA86 1 0.2 1 100.0 0 0.0 0 0.0
ST2947-V [5C2] (WA129) 1 0.2 0 0.0 1 100.0 1 100.0
Total 240 59.6 61 25.4 179 74.6 90 37.5
Grand total 403 100.0 137 34.0 266 66.0 91 22.6
PVL Panton-Valentine leucocidin.
* Percentage of all methicillin-resistant Staphylococcus aureus (MRSA).
† Percentage of the strain.
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Three HA-MRSA clones were identified: 119 iso-
lates of ST22-IV [2B] (EMRSA-15) (29.5% of 
MRSA and 5.4% of S. aureus); 43 isolates of ST239-
III [3A] (Aus -2/3 EMRSA) (10.7% and 1.9%) and 
a single isolate of ST5-II [2A] (USA100/New York 
Japan MRSA).
ST22-IV [2B] (EMRSA-15) was the dominant 
HA-MRSA clone in Australia accounting for 73% 
of HA-MRSA ranging from 0% in the Northern 
Territory to 100% in Tasmania and Western 
Australia (Table 4). ST22-IV [2B] (EMRSA-15) 
was typically PVL negative and using CLSI break-
points 98.3% and 61.3% were ciprofloxacin and 
erythromycin resistant respectively.
ST239-III [3A] (Aus-2/3 EMRSA) accounted 
for 26.4% of HA-MRSA ranging from 0% in 
Tasmania and Western Australia to 100% in 
the Northern Territory (Table 4). PVL negative 
ST239-III [3A] (Aus-2/3 EMRSA) were typically 
resistant to erythromycin (97.7%), co-trimoxazole 
(100%), ciprofloxacin (97.7%), gentamicin (97.7%), 
tetracycline (79%) and clindamycin (74.4%).
Community-associated methicillin-resistant 
Staphylococcus aureus
For the 240 CA-MRSA strains, 25.4% (61) of epi-
sodes were epidemiologically classified as hospital 
onset and 74.6% (179) classified as community 
onset. Twenty-six different CA-MRSA clones 
were identified by pulsed-field gel electrophoresis 
(PFGE) corresponding to 19 MLST/SCCmec 
clones (Table 3). Overall, 77.5% of CA-MRSA 
were classified into 6 clones each having more than 
10 isolates: ST93-IV [2B] (Queensland CA-MRSA) 
(14.9% of MRSA and 2.7% of S. aureus); ST1-IV 
[2B] (WA1) (11.2% and 2%); ST45-V [5C2&5] 
(WA84) (7.4% and 1.4%); ST30-IV [2B] (South 
West Pacific [SWP] CA-MRSA) (5.0% and 0.9%); 
ST5-IV [2B] (WA3) (4.2% and 0.8%); and ST78-IV 
[2B] (WA2) (2.7% and 0.5%).
ST93-IV [2B] (Queensland CA-MRSA) 
accounted for 25% of CA-MRSA ranging from 0% 
in Tasmania and the Australian Capital Territory 
to 59.1% in the Northern Territory (Table 5). 
Typically PVL positive, 83.3% of ST93-IV [2B] 
(Queensland CA-MRSA) were resistant to the 
ß-lactams only (50/60) or additionally resistant to 
erythromycin (10%, 6/60), erythromycin and clin-
damycin (5%, 3/60), or erythromycin, clindamycin 
and ciprofloxacin (1.7%, 1/60).
ST1-IV [2B] (WA1) accounted for 18.8% of 
CA-MRSA ranging from 0% in Tasmania to 100% 
in the Australian Capital Territory (Table 5). 
Typically PVL negative, 62.2% of isolates were 
resistant to the ß-lactams only (28/45) or addition-
ally resistant to erythromycin (8.9%, 4/45), eryth-
romycin and fusidic acid (8.9%, 4/45), high level 
mupirocin (6.7%, 3/45), ciprofloxacin, erythromy-
cin and fusidic acid (4.4%, 2/45), ciprofloxacin, 
erythromycin and gentamicin (2.2%, 1/45), clin-
damycin (2.2%, 1/45), erythromycin, fusidic acid 
and nitrofurantoin (2.2%, 1/45) or nitrofurantoin 
(2.2%, 1/45).
ST45-V [5C2&5] (WA84) accounted for 12.5% of 
CA-MRSA and was isolated primarily in the east-
ern regions of Australia (Table 5). All isolates were 
PVL negative and were resistant to the ß-lactams 
and ciprofloxacin. Isolates were additionally non-
susceptible to erythromycin and tetracycline (20%, 
6/30), erythromycin, gentamicin and tetracycline 
(16.7%, 5/30), erythromycin and gentamicin 
(13.3%, 4/30), erythromycin and clindamycin 
(10%, 3/30) and one (3.3%) each of erythromycin 
or erythromycin, clindamycin and tetracycline 
or erythromycin, clindamycin, gentamicin and 
tetracycline or clindamycin, erythromycin and 
nitrofurantoin or erythromycin, nitrofurantoin, 
gentamicin and tetracycline or erythromycin, 
fusidic acid, gentamicin and tetracycline.
ST30-IV [2B] (SWP CA-MRSA), accounted for 
8.3% of CA-MRSA and was primarily isolated in 
the eastern regions of Australia (Table 5). Typically 
PVL positive, 70% of isolates were resistant to 
the ß-lactams only (14/20). Six isolates were non-
susceptible to nitrofurantoin (30%).
ST5-IV [2B] (WA3) accounted for 8.3% of 
CA-MRSA and was primarily isolated in the east-
ern regions of Australia (Table 5). PVL negative 
ST5-IV [2B] (WA3) was typically resistant to the 
ß-lactams only (50%, 10/20) or additionally resist-
ant to erythromycin (20%, 4/20), erythromycin 
and high level mupirocin (11.5%, 3/20), erythro-
mycin and fusidic acid (5% 1/20), erythromycin 
and rifampicin (5% 1/20) or high level mupirocin 
(5%, 1/20).
ST78-IV [2B] (WA2), accounted for 4.6% of 
CA-MRSA and was isolated in most regions of 
the Australian mainland (Table 5). Isolates were 
resistant to the ß-lactams only (27%, 3/11) or addi-
tionally resistant to erythromycin (63.6%, 7/11). 
One isolate was resistant to tetracycline.
Overall, 85.8% of CA-MRSA were non-multire-
sistant and 50.4% were resistant to the ß-lactams 
only. However, 34 (14.2%) CA-MRSA isolates were 
multiresistant.
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Panton-Valentine leucocidin
Overall 91 (22.6%) MRSA were PVL positive, of 
which 98.9% were CA-MRSA (Table 3). PVL posi-
tive CA-MRSA clones included the international 
CA-MRSA clone ST8-IV [2B] USA300.
Discussion
The AGAR surveillance programs collect data on 
antimicrobial resistance, focussing on bloodstream 
infections caused by S. aureus, Enterococcus and 
Enterobacteriaceae. All data being collected in the 
AGAR programs are generated as part of routine 
patient care in Australia, with most being available 
through laboratory and hospital bed management 
information systems. Isolates are referred to a 
central laboratory where strain and antimicro-
bial resistance determinant characterisation is 
performed. As the programs are similar to those 
conducted in Europe comparison of Australia 
antimicrobial resistance data with other countries 
is possible.19
In the 2013 European Centre for Disease 
Prevention and Control and Prevention SAB 
surveillance program, the European Union/
European Economic Area (EU/EEA) population-
weighted mean percentage of S. aureus resistant 
to methicillin was 18.0% (95% CI 17–20), ranging 
from 0.0% (95% CI 0–5) in Iceland to 64.5% (95% 
CI 59–69) in Romania.20 In ASSOP 2014, 18.8% 
(95% CI 17.2–20.5) of the 2,206 SAB episodes 
were methicillin resistant. This compares with 
19.1% (95% CI 17.5–21.0) in ASSOP 2013. Two 
European countries reported a similar percentage 
to Australia: Bulgaria (19.2%, 95% CI 14–25), and 
Ireland (19.9%, 95% CI 18–2). However for 18 of 
the 30 European countries (primarily the north-
ern Europe countries, Germany, France and the 
United Kingdom) the percentage of SAB isolates 
resistant to methicillin was less than that reported 
in ASSOP 2014. Similar to Europe, which has seen 
the EU/EEA population-weighted mean percent-
age decrease significantly from 23.2% in 2009 
to 18.0% in 2013, the percentage of methicillin-
resistant SAB in Australia has decreased from 
23.8% (95% CI 21.4–26.4) in 2007 to 18.8% (95%CI 
17.2–20.5) in 2014 (P < 0.0001).21 The decrease in 
methicillin-resistant SAB is consistent with what 
has been reported elsewhere22,23 and is believed to 
be attributed to the implementation of antimicro-
bial stewardship and a package of improved infec-
tion control procedures including hand hygiene, 
MRSA screening and decolonisation, patient iso-
lation and infection prevention care bundles.24–28 
However, unlike Europe, Australia has a high 
prevalence of CA-MRSA and so further reduction 
in the proportion of SAB due to MRSA may prove 
problematic.
In ASSOP 2014, the all-cause mortality at 30-days 
was 16.1% (95% CI 14.5–17.8). In comparison, 
the 2008 Australian New Zealand Cooperative 
on Outcomes in Staphylococcal Sepsis reported 
a significantly higher figure of 20.6% (95% CI 
18.8–22.5, P < 0.0001), and when adjusted for 
Australian institutions only was 25.9% (personal 
communication). MRSA-associated SAB mortality 
remains high (23.4%, 95% CI 19.1–28.1) and was 
significantly higher than MSSA-associated SAB 
mortality (14.4%, 95% CI 12.7–16.3, P < 0.0001). 
Although it has recently been shown that invasive 
MRSA infection may be more life-threatening 
partially because of the inferior efficacy of the 
standard treatment, vancomycin,9 the emergence 
of hyper-virulent CA-MRSA clones such as 
ST93-IV [2B] (Queensland CA-MRSA), causing 
healthcare-associated SAB is of concern.29
With the exception of the ß-lactams and erythro-
mycin, antimicrobial resistance in MSSA remains 
rare. However, in addition to the ß-lactams 
approximately 50% of MRSA were resistant to 
erythromycin and ciprofloxacin and approximately 
15% resistant to co-trimoxazole, tetracycline and 
gentamicin. Resistance was largely attributable to 
2 healthcare-associated MRSA clones, ST22-IV 
[2B] (EMRSA-15), which is typically ciprofloxacin 
and erythromycin resistant, and ST239-III [3A] 
(Aus-2/3 EMRSA), which is typically erythromy-
cin, clindamycin, ciprofloxacin, co-trimoxazole, 
tetracycline and gentamicin resistant. From the 
early 1980s until recently, the multi-resistant 
ST239-III [3A] (Aus-2/3 EMRSA) was the domi-
nant HA-MRSA clone in Australian hospitals. 
However, ST22-IV [2B] (EMRSA-15) has replaced 
it as the most prevalent HA-MRSA isolated from 
clinical specimens and this change has occurred 
throughout most of the country.30 In the current 
survey, ST239-III [3A] (Aus-2/3 EMRSA) was the 
only HA-MRSA clone in the Northern Territory. 
In ASSOP 2014, approximately 30% of MRSA 
were characterised as ST22-IV [2B] (EMRSA-15), 
compared with 24% in ASSOP 2013. CA-MRSA, 
in particular the ST45-V [5C2&5] (WA84) clone, 
has acquired multiple antimicrobial resistance 
determinants including ciprofloxacin, erythromy-
cin, clindamycin, gentamicin and tetracycline.
Resistance was not detected for vancomycin, 
linezolid or teicoplanin when CLSI interpretive 
criteria were applied. However two isolates were 
teicoplanin non-susceptible when EUCAST crite-
ria were applied.
Approximately 25% of SAB caused by CA-MRSA 
were of healthcare onset. Although in several parts of 
the United States of Australia the CA-MRSA clone 
USA300 has replaced the HA-MRSA clone ST5-II 
[2A] (USA100) as a cause of healthcare-associated 
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MRSA infection,31 transmission of CA-MRSA 
in Australian hospitals is thought to be rare.32,33 
Consequently it is likely that many of the health-
care onset CA-MRSA SAB infections reported 
in ASSOP 2014 were caused by the patient’s own 
colonising strains acquired prior to admission. In 
Australia CA-MRSA clones such as PVL-positive 
ST93-IV [2B] (Queensland CA-MRSA) and PVL-
negative ST1-IV [2B] (WA1) are well established 
in the community and therefore it is important to 
monitor antimicrobial resistance patterns in both 
community– and healthcare-associated SAB as 
this information will guide therapeutic practices 
in treating S. aureus sepsis.
In conclusion, ASSOP 2014 has demonstrated 
antimicrobial resistance in SAB in Australia is a 
significant problem and continues to be associated 
with a high mortality. This may be due, in part, 
to the high prevalence of methicillin-resistant 
SAB in Australia, which is significantly higher 
than most EU/EEA countries. Consequently, 
MRSA must remain a public health priority and 
continuous surveillance of SAB and its outcomes 
and the implementation of comprehensive MRSA 
strategies targeting hospitals and long-term care 
facilities are essential.
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